International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

COVID-19 Sequelae in Recovered Patients: A Comprehensive Narrative Review of Post-Acute Effects, Organ Involvement, and Clinical Management

Dr. Hridesh Singh Patel

Consultant Physician, District Hospital Banda, Uttar Pradesh

Abstract

COVID-19 recovery is not always complete at the end of the acute infection. A substantial subset of survivors develops persistent or relapsing symptoms, sometimes termed long COVID or post-COVID-19 condition. This narrative review synthesizes current evidence on the major sequelae seen in recovered patients, with emphasis on respiratory, cardiovascular, neurological, neuropsychiatric, and pediatric manifestations. Contemporary public-health guidance defines long COVID as a chronic condition that appears after SARS-CoV-2 infection and can last for months or years, with no single diagnostic test and no universally curative therapy. Across large systematic reviews, the most common persistent symptoms include fatigue, dyspnea, cognitive dysfunction, anxiety, depression, and sleep disturbance, while organ-specific outcomes include myocardial injury, dysautonomia, interstitial lung disease, reduced exercise tolerance, and post exertional symptom worsening. Mechanistic models increasingly support a multifactorial syndrome involving viral persistence, immune dysregulation, endothelial injury, autonomic dysfunction, microvascular abnormalities, and altered gut-brain signaling. Evidence-based management remains symptom-directed and multidisciplinary, combining rehabilitation, mental health support, careful assessment for alternative diagnoses, and risk reduction through vaccination and prevention of severe acute disease. The review concludes that the sequelae of COVID-19 represent a major long-term public-health burden and that future progress depends on standardized definitions, biomarkers, phenotype-driven care pathways, and trials of targeted therapies.

Keywords: COVID-19, long COVID, post-acute sequelae of SARS-CoV-2, rehabilitation, cardiovascular complications, neurocognitive symptoms.

1. Introduction

COVID-19 has evolved from an acute infectious disease crisis into a chronic post-infectious health problem for millions of survivors. The clinical picture is broader than lingering cough or tiredness. Major public-health agencies now define long COVID as a chronic condition after SARS-CoV-2 infection, typically present for at least three months, and capable of affecting multiple organ systems [1-3]. WHO notes that symptoms may appear three months after infection and last at least two months, while CDC emphasizes that the syndrome can persist for months to years and may fluctuate, improve, worsen, or reemerge [1-4]. 3 The burden is substantial. WHO has estimated that roughly 10–20% of

infected people may develop long COVID, and CDC continues to describe it as a serious illness that can require comprehensive care and sometimes cause disability [1-3]. A 2024 meta-analysis of 211 studies including more than 13 million people found that fatigue, dyspnea, post-traumatic stress disorder, anxiety, and depression were among the most frequently reported persistent symptoms [11]. In practice, this means that the post-acute phase of COVID-19 is not simply a recovery period; for many patients it is a distinct chronic disease trajectory. This paper reviews the evolving literature on COVID-19 sequelae in recovered patients, focusing on the systems most often affected and the clinical implications for diagnosis, followup, rehabilitation, and prevention.

Review Approach This paper is a narrative review based on recent peer-reviewed reviews, meta-analyses, consensus statements, and public-health guidance published during and after the pandemic. Priority was given to authoritative sources from WHO and CDC, followed by high-level evidence from PubMed-indexed systematic reviews and clinical reviews. The aim was to synthesize the current state of knowledge rather than reproduce a single-study dataset.

2. Definitions, Terminology, and Epidemiology

Multiple terms have been used for the condition, including long COVID, post-COVID-19 condition, post-acute sequelae of SARS-CoV-2 infection (PASC), and post-COVID syndrome. WHO's case definition emphasizes the onset or persistence of symptoms three months after acute infection, lasting at least two months, with no alternative explanation [1]. CDC's clinical framing is somewhat broader, describing a chronic condition that occurs after SARS-CoV-2 infection and is present for at least three months [2,3]. The epidemiology varies across studies because definitions, follow-up periods, and case ascertainment differ. This heterogeneity is one reason prevalence estimates range widely. Nonetheless, large systematic reviews consistently show that a meaningful minority of survivors develop persistent symptoms, and the risk is higher in those with severe acute illness, multiple comorbidities, longer hospitalization, female sex, older age, and higher body mass index [11,18,23,24]. Pediatric disease is also real, although some studies suggest a lower overall prevalence than in adults [22-24]. 4 Public-health reporting from CDC underscores that long COVID affects children as well as adults and that repeated SARS-CoV-2 infections may carry repeated risk [2,3]. The syndrome is therefore best understood as a population-level chronic consequence of a highly transmissible viral infection, not as a rare complication limited to severe acute cases.

3. Pathophysiology

No single mechanism explains all cases. The dominant model is multifactorial and includes incomplete viral clearance or viral persistence, immune dysregulation, ongoing low-grade inflammation, endothelial dysfunction, microvascular injury, autonomic imbalance, and altered tissue repair [7-10,14]. Reviews in 2024 emphasized that long COVID is likely an umbrella syndrome with several overlapping biological endotypes rather than one disease entity [7,9,10,14]. Immune and inflammatory hypotheses remain central. Persistent immune activation may maintain symptoms such as fatigue, pain, sleep disturbance, and cognitive dysfunction. Some reviews also highlight gut-brain axis disruption and intestinal inflammation, which may contribute to systemic symptom persistence [7,9,14]. Endothelial injury and microvascular dysfunction provide a plausible explanation for dyspnea, chest pain, exercise intolerance,

and neurologic complaints in the absence of major structural abnormalities [10,13,14]. Autonomic dysfunction is another recurring theme. Many patients experience palpitations, orthostatic dizziness, and reduced exercise tolerance, consistent with dysautonomia or postural orthostatic tachycardia syndrome-like phenotypes [13,14]. At the same time, separate phenotypes may be driven primarily by organ damage during acute infection, such as post-ARDS lung disease or myocarditis-related sequelae [15-17]. The clinical task is therefore to distinguish between ongoing inflammation, residual organ injury, and post-infectious functional syndromes.

4. Respiratory and Pulmonary Sequelae

Pulmonary sequelae are among the most common and functionally important outcomes after COVID-19. Persistent cough, dyspnea, chest tightness, and exercise limitation may follow acute pneumonia or acute respiratory distress syndrome, but even patients without prolonged hospitalization can develop lingering respiratory symptoms [11,15-17]. Chest-CT follow-up studies and systematic reviews show that a subset of survivors have residual radiologic abnormalities, including ground-glass opacities, reticulation, and fibrotic-like change [16,17]. 5 Post-COVID interstitial lung disease and pulmonary fibrosis are particularly concerning because they can reduce diffusing capacity, impair exercise capacity, and prolong recovery [15- 17]. The literature suggests that fibrosis risk is linked to the severity of the initial inflammatory insult, prolonged ventilation, and host factors that alter repair pathways [15,18]. However, the exact natural history remains uncertain, and not all radiologic abnormalities translate into permanent disability. Rehabilitation is an important treatment pillar. Pulmonary rehabilitation has been associated with improved dyspnea, physical function, and quality of life in long COVID populations [26]. Because breathlessness may also reflect cardiac disease, dysautonomia, anemia, deconditioning, or anxiety, a careful differential diagnosis is essential before attributing all symptoms to lung injury alone [3,26].

5. Cardiovascular Sequelae

Cardiovascular manifestations include palpitations, chest pain, tachycardia, exercise intolerance, orthostatic symptoms, thromboembolic disease, and, in some patients, evidence of myocardial injury [13-15]. Reviews and consensus statements have described long COVID as a contributor to cerebrovascular disease, dysrhythmias, inflammatory heart disease, and cardiopulmonary symptoms [13-15]. The pathophysiology is again heterogeneous. Some patients likely have residual myocardial or vascular injury after acute infection, whereas others show a syndrome dominated by autonomic dysfunction or microvascular dysregulation [13-15]. Cardiac sequelae may occur even in people without prior cardiovascular disease, making symptom-based screening important when patients report chest pain, exertional dyspnea, fainting, or palpitations after recovery [14,15]. The clinical literature suggests that pre-existing cardiovascular disease and severe acute infection increase the risk of persistent symptoms, while a multimorbidity burden may worsen prognosis [11,13]. Consensus guidance recommends stepwise evaluation rather than overreliance on a single laboratory or imaging test [3,26,27].

6. Neurological and Cognitive Sequelae

Neurological sequelae are now recognized as a core component of the syndrome. Patients frequently report headache, dizziness, paresthesias, sleep disturbance, cognitive slowing, 6 memory problems, and difficulty concentrating, often described colloquially as brain fog [11,19,20]. Systematic reviews have

found measurable burdens of cognitive and mental-health symptoms, although the phenotype is not uniform [19,20]. The mechanisms remain under active study. Neuroinflammation, endothelial injury, autoimmunity, altered cerebral perfusion, and persistent immune activation are all plausible contributors [9,14,19]. Importantly, cognitive symptoms may coexist with mood disorders, posttraumatic stress symptoms, and fatigue, making the clinical picture more complex than isolated memory impairment [11,19,20]. Because brain fog can significantly impair school performance, work capacity, and daily functioning, a practical approach includes screening for sleep disorders, depression, medication effects, thyroid dysfunction, anemia, and other treatable contributors while validating the symptom burden reported by the patient [3,19,20].

7. Mental Health and Quality of Life

Psychiatric and psychological symptoms are common and clinically meaningful. A large meta-analysis found that post-traumatic stress disorder, anxiety, and depression were among the most frequent persistent symptoms after COVID-19 [11]. Another systematic review found a substantial burden of depression, anxiety, and sleep disorders among people recovering from COVID-19 [20]. These outcomes are shaped by both biology and lived experience. Survivors may face prolonged symptoms, uncertainty, social isolation, financial stress, and reduced function, all of which can worsen psychological distress. At the same time, inflammatory and neurobiological changes may contribute directly to mood and cognition changes [9,19,20]. Evidence for treatment is emerging. A 2024 systematic review of interventions found that rehabilitation-based and psychological approaches can improve selected outcomes, and later living reviews continue to evaluate therapy options for long COVID symptoms [25,26]. Even so, supportive care, symptom validation, and coordinated mental-health referral remain fundamental.

8. Pediatric and Adolescent Sequelae

Children and adolescents can develop post-acute sequelae, although prevalence and symptom patterns may differ from adults [22-24]. Pediatric long COVID may include fatigue, headache, dizziness, concentration difficulties, abdominal pain, dyspnea, and school absenteeism 7 [22,23]. Some pediatric patients also develop autonomic symptoms or conditions resembling chronic fatigue syndromes [22-24]. Risk-factor reviews suggest that female sex, asthma, comorbidity, and heart disease may increase the likelihood of long COVID in young people, though the evidence base is still evolving [23]. Children therefore require age-appropriate assessment that considers educational impact, emotional health, sleep, and family burden, not just symptom counts [22,23]. The presence of pediatric disease reinforces the broader public-health message: SARSCoV-2 is not only an acute respiratory pathogen. It can leave a long tail of morbidity across the life course [1-3,22-24].

9. Diagnosis and Clinical Management

Long COVID remains a clinical diagnosis. CDC notes that there is currently no approved laboratory test that can confirm or exclude the condition, and objective findings should not be used as the sole measure of patient well-being [2,3]. Evaluation should begin with history, timing of symptoms, acute COVID-19 severity, vaccination history, comorbidities, and functional decline. Clinicians must also search for alternative or coexisting diagnoses such as anemia, pulmonary embolism, arrhythmia, heart failure,

thyroid disease, autoimmune disease, sleep apnea, or mood disorders [3,26,27]. Management is symptom-directed and multidisciplinary. Current guidance emphasizes patient-centered goals, shared decision-making, validation of symptoms, and matching interventions to the dominant phenotype [3,26,27]. Rehabilitation can help with deconditioning, dyspnea, and reduced endurance [26]. Psychological support may improve anxiety, depression, and coping [20,25]. In cardiopulmonary phenotypes, stepwise testing and specialist referral are important, especially when chest pain, syncope, exertional desaturation, or new arrhythmias are present [13-15,26,27]. There is no universally effective drug therapy yet, but the evidence base is expanding. Systematic reviews of interventions show possible benefit from rehabilitation, cognitivebehavioral and psychological approaches, and other targeted therapies in selected groups [25,26]. Future treatment is likely to depend on phenotype-specific mechanisms rather than a single onesize-fits-all solution [7,10,14].

10. Prevention and Public-Health Implications

Prevention begins with reducing the risk of SARS-CoV-2 infection and severe acute disease. WHO recommends vaccination/boosters, masking in appropriate settings, hand hygiene, cough etiquette, and ventilation as measures that also reduce long-COVID risk indirectly by preventing infection in the first place [1]. CDC similarly emphasizes vaccination as the best available means of preventing long COVID [3]. From a health-system perspective, long COVID requires longitudinal care pathways, rehabilitation access, and better surveillance. CDC surveillance pages continue to monitor prevalence and disability burden because the condition affects adults and children and can persist for years [2,3]. The economic impact includes lost schooling, reduced work capacity, and increased utilization of primary care and specialty services. Research priorities include standardized phenotyping, harmonized outcome measures, biomarker discovery, subgroup analyses by age and comorbidity, and randomized trials of targeted therapies. The most important conceptual shift is that recovery from COVID-19 should not be assumed at the point when the acute infection ends.

11. Conclusion

COVID-19 sequelae in recovered patients represent a broad, multisystem post-viral syndrome with major clinical and societal consequences. The evidence supports a model in which long COVID arises from overlapping biological mechanisms and manifests through heterogeneous respiratory, cardiovascular, neurological, psychological, and pediatric phenotypes. Because there is no single diagnostic test or curative treatment, the practical response must be comprehensive, patient-centered, and multidisciplinary [1-3,7-10,25-27]. The key challenge for the next phase of research is to move from broad syndrome descriptions toward mechanism-linked subtypes that can be diagnosed more precisely and treated more effectively. Until then, clinicians should recognize persistent symptoms, rule out dangerous alternatives, and provide supportive, rehabilitation-based care that restores function and quality of life as much as possible.

References

1. World Health Organization. Post COVID-19 condition (Long COVID). Fact sheet. 7 Dec 2022.
2. Centers for Disease Control and Prevention. Long COVID Basics. 2026.
3. Centers for Disease Control and Prevention. Long COVID Clinical Guidance. 2026.
4. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. 2026. 9
5. Greenhalgh T, et al. Long COVID: a clinical update. The Lancet. 2024.
6. Ely EW, et al. Long COVID Defined. New England Journal of Medicine. 2024.
7. Peluso MJ, et al. Mechanisms of long COVID and the path toward therapeutics. 2024.
8. Castanares-Zapatero D, et al. Pathophysiology and mechanism of long COVID. 2022.
9. Gusev E, et al. Exploring the Pathophysiology of Long COVID. 2024.
10. Bakerly ND, et al. Pathophysiological Mechanisms in Long COVID: A Mixed Methods Review. 2024.
11. Luo D, et al. Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2024.
12. Han Q, et al. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-analysis. 2022.
13. Tsampasian V, et al. Cardiovascular disease as part of Long COVID. 2024.
14. Krug E, et al. Cardiovascular Manifestations of Long COVID: A Review. 2024.
15. Ramadan MS, et al. Cardiac sequelae after coronavirus disease 2019 recovery. 2021.
16. Cha MJ, et al. Chronic Lung Injury after COVID-19 Pneumonia. 2024.
17. Babar M, et al. Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: a systematic review and meta-analysis. 2024.
18. Duong-Quy S, et al. Tackling pulmonary fibrosis risks in post-COVID-19. 2025.
19. van der Feltz-Cornelis C, et al. Prevalence of mental health conditions and brain fog in people with long COVID. 2024.
20. Seighali N, et al. Global prevalence of depression, anxiety, and sleep disorders among individuals recovering from COVID-19. 2024.
21. Hawke LD, et al. Systematic review of interventions for mental health, cognition and psychological well-being in long COVID. 2024.
22. Rao S, et al. Postacute Sequelae of SARS-CoV-2 in Children. 2024.
23. Toepfner N, et al. Long COVID in pediatrics—epidemiology, diagnosis, and management. 2024.
24. Rayner DG, et al. Risk factors for long COVID in children and adolescents. 2024.
25. Zeraatkar D, et al. Interventions for the management of long covid (post-COVID-19 condition). 2024/2025.
26. Zhang Y, et al. Clinical practice guidelines and expert consensus recommendations for rehabilitation of long COVID. 2024.
27. Cheng AL, et al. Multidisciplinary collaborative guidance on the assessment and treatment of adults with Long COVID. 2025.